Abstract
The purpose of this study was to compare the effects of Cyclosporine A (CyA) and FK506 on bone mass and mineral metabolism in liver transplantation (LT) patients. A prospective study was performed on 18 male patients who underwent LT treated with CyA, and 7 LT patients who received FK506. Bone mineral density (BMD) of the lumbar spine and proximal femur (DPX-L) was measured before and at 6, 12, and 24 months after transplantation. Moreover, intact parathyroid hormone (PTH) and 25-hydroxyvitamin D (25OHD) levels were determined at the same time. The cumulative dose of glucocorticoids was calculated in all patients. At 6 months, lumbar BMD decreased 5.2 ± 1.2 % (P=0.0005) and 2.9 ± 2.1 % (p=ns) in CyA and FK506 groups, respectively. Lumbar BMD reached baseline values at 1 year in the FK506 group and 2 years after LT in the CyA group. Moreover, significant intergroup differences in femoral neck BMD changes after 2 years of transplant were observed (CyA: −5.2 ± 1.97 versus FK506: +1.55 ± 2.2 %;P=0.039). In the first year posttransplant both groups showed a marked increase in PTH and 25OHD levels. The mean cumulative dose of glucocorticoids was higher in the CyA group (CyA group 11.06 ± 0.46 g versus FK 506 group 6.71 ± 0.42 g;P<0.001), and multiple linear regression analysis showed a negative correlation between BMD changes at the lumbar spine and mean cumulative dose of glucocorticoids (P=0.022). In conclusion, our data suggest that after liver transplantation treatment with FK506 shows a more favorable long-term effect on bone mass evolution than CyA therapy. These differences seem to be associated with the lower dose of glucocorticoids used in the FK506 group.
Similar content being viewed by others
References
Navasa M, Monegal A, Guañabens N, Peris P, Rimola A, Muñoz-Gómez J, Visa J, Rodés J (1994) Bone fractures in liver transplant patients. Br J Rheumatol 33:52–55
Porayko MK, Wiesner RH, Hay JE, Krom RAF, Dickson ER, Beaver S, Schwerman L (1991) Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 23:1462–1465
McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Sheil AGR, Evans RA, McCaughan GW (1991) Bone loss after liver transplantation. Hepatology 14:613–619
Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WSS, Epstein S (1994) The deleterious effects of long-term Cyclosporine A, Cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57:1231–1237
Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S (1988) Cyclosporine A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 123:2571–2577
Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Porticell C (1997) Effects of three immunosuppresive regimens on vertebral bone density in renal transplant recipients. Transplantation 63:380–386
Eberwein S, Leiding-Brukner G, Czeczatka D, Pristsch M, Klose C, Otto G, Theilmann L, Ziegler R (1997) Comparison of FK506 and Cyclosporine A in regard to the development of osteoporosis following liver transplantation. J Bone Miner Res 12 (suppl 1):S401
Stempfle HU, Werner C, Echtler S, Assun T, Meiser B, Angermann CE, Theisen K, Gärtner R (1998) Rapid trabecular bone loss after cardiac transplantation using FK506 (Tacrolimus)-based immunosuppresion. Transplant Proc 30:1132–1133
Park KM, Hay JE, Lee SG, Wiesner RH, Porayko MK, Krom RAF (1996) Bone loss after liver transplantation: FK506 versus Cyclosporine. Transplant Proc 28:1738–1740
Pugh RNH, Murray-Lyon IM, Dawson SL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649
Meys E, Fontanges E, Fourcade N, Thomasson A, Puoyet M, Delmas PD (1994) Bone loss after orthotopic liver transplantation. Am J Med 97:445–450
Crosbie OM, Franey R, McKenna MJ, Cirry MP, Hegarty JE (1999) Predicting bone loss following orthotopic liver transplantation. Gut 44:430–434
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Monegal, A., Navasa, M., Guañabens, N. et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 68, 83–86 (2001). https://doi.org/10.1007/BF02678145
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02678145